Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics Inc. (LSTA) is a clinical-stage biopharmaceutical company pioneering novel peptide-based therapies for advanced solid tumors. This dedicated news hub provides investors and researchers with essential updates on the company's progress in enhancing cancer treatment through innovative drug delivery systems.
Access timely reports on clinical trial developments, strategic research partnerships, and regulatory milestones related to Lisata's lead candidate certepetide and its CendR Platform technology. Our curated collection includes press releases on trial initiations, scientific presentations, and corporate announcements that demonstrate the company's evolving role in oncology therapeutics.
Key updates cover advancements in pancreatic cancer research, glioblastoma treatment studies, and collaborative projects with academic institutions. The resource serves as a centralized reference for tracking how Lisata's tumor-penetrating peptide technology may improve existing cancer treatment paradigms through enhanced drug delivery mechanisms.
Bookmark this page for structured access to verified information about Lisata's clinical programs and corporate developments. Check regularly for new insights into the company's efforts to address unmet needs in solid tumor oncology through targeted therapeutic strategies.
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, a clinical-stage pharmaceutical company, announced that CEO David J. Mazzo, PhD, will present at three upcoming conferences:
- LSX World Congress: May 3-4, 2023 in London. Dr. Mazzo's presentation will be on May 3 at 11:15 a.m. British Summer Time.
- Sidoti Micro-Cap Conference: May 10-11, 2023, virtual. Dr. Mazzo will present on May 10 at 10:00 a.m. Eastern Time.
- Bio€quity Europe 2023: May 14-16, 2023 in Dublin. Dr. Mazzo's presentation is set for May 15 at 1:41 p.m. Irish Standard Time.
Lisata develops innovative therapies for advanced solid tumors and is advancing its lead candidate, LSTA1, designed to enhance anti-cancer drug delivery while minimizing effects on normal tissues. The company is actively exploring treatment modalities for various solid tumors.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
